The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide ...
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
The NYPD confirmed the shooting, which caused UnitedHealth to end an investor conference early on Wednesday. Thompson, 50, ...
A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...